DNAnexus Announces Appointment of Thomas Laur as CEO
Proven healthcare executive brings decades of experience leading successful software, data, and services companies
Richard Daly remains actively involved as a member of the Board of Directors
MOUNTAIN VIEW, Calif., — September 12, 2023 — DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data management and analysis software, today announced that Thomas Laur has been appointed Chief Executive Officer and member of the company’s Board of Directors, effective September 11, 2023. Mr. Laur succeeds Richard Daly, who has overseen the company’s significant growth since 2013 and will remain an active advisor and a member of the Board of Directors.
“It has been the greatest privilege of my life to have led the evolution of DNAnexus from a small startup of 15 people a decade ago to the leader in precision health informatics,” said Mr. Daly. “It’s an honor to know that our rapidly growing global user community has been responsible for many key scientific and clinical advances in human health, advances that are accelerating with the growing importance of precision health data. Passing the CEO title to an exceptional leader like Thomas ensures our future success.”
Michael Goldberg, Executive Chair of the DNAnexus Board of Directors, commented: “Today’s announcement is the result of thoughtful succession planning. We are thrilled to have Thomas lead DNAnexus through our next phase of growth to help meet the increasing global demand for technologies that harness the power of biomedical data. On behalf of the Board, I want to thank Dick for his essential role in establishing DNAnexus as the leading cloud-based precision health company serving the global life science community. He was responsible for driving the company’s strong international growth, new technology integrations, and core platform advancements. We look forward to continuing to work with him as an advisor and Board member.”
Mr. Laur brings more than 25 years of international experience leading software, data, and services companies in the healthcare space. Most recently, he served as EVP and President of the Technology Enabled Services division at Change Healthcare, which combined with Optum, part of UnitedHealth Group (NYSE: UNH), in October 2022. Previously, Mr. Laur was President, Healthcare at SAP, holding end-to-end responsibility for the company’s global healthcare business. Earlier in his career, Mr. Laur served as CEO at both Sutherland Healthcare Solutions and Cognizant Healthcare Ventures, where he focused on incubating new business models and scaling operations. Mr. Laur spent the first decade of his career in corporate strategy and management consulting, where he focused on M&A, innovation, and operational transformation.
Following years of sustained growth that have established DNAnexus as the recognized leader in precision health data management and analysis, Mr. Laur will further scale the company’s global operations with a focus on platform innovation and customer experience.
“At a time of accelerating innovation in multiomics research and bioinformatics, I am honored to lead the next chapter at DNAnexus,” said Mr. Laur. “Working alongside Dick, our Board, and the entire DNAnexus team, I am confident that we will further solidify the company’s leadership as the premier precision health data cloud provider and continue to power a global network for scientific collaboration at the apex of precision medicine.”
DNAnexus is a leading provider of secure, scalable, and intuitive biomedical data analysis software and bioinformatics applications for the life sciences and healthcare communities. The company actively manages and supports more than 80 petabytes of complex genomic, multi-omic, and clinical datasets on behalf of a growing network of collaborations with large-scale biobanks, as well as leading pharmaceutical, clinical diagnostic, academic research, and government organizations. Scientists across 48 countries are now using the highly collaborative, cloud-based, end-to-end platform to gain data-driven insights that can advance scientific discovery, accelerate precision medicine, and improve patient care.